Interpace Biosciences, Inc. IDXG
We take great care to ensure that the data presented and summarized in this overview for INTERPACE BIOSCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in IDXG
Top Purchases
Top Sells
About IDXG
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Insider Transactions at IDXG
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 01
2024
|
Christopher Mc Carthy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+17.97%
|
-
|
Jul 31
2023
|
Christopher Mc Carthy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+41.22%
|
-
|
May 21
2021
|
Thomas W. Burnell President & CEO |
BUY
Open market or private purchase
|
Indirect |
10,855
+50.0%
|
$86,840
$8.68 P/Share
|
Mar 10
2021
|
Thomas John Freeburg Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+49.02%
|
-
|
Mar 01
2021
|
Peter Kamin > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,840
+5.92%
|
$77,520
$3.08 P/Share
|
Mar 01
2021
|
Peter Kamin > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
16,360
+5.71%
|
$49,080
$3.08 P/Share
|
Feb 26
2021
|
Peter Kamin > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
26,104
+6.35%
|
$78,312
$3.17 P/Share
|
Feb 26
2021
|
Peter Kamin > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
14,946
+5.56%
|
$44,838
$3.17 P/Share
|
Jan 29
2021
|
Robert J. Gorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,438
+39.87%
|
$49,752
$4.02 P/Share
|
Dec 01
2020
|
Thomas W. Burnell President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+33.24%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 10K shares |
---|